The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.
about
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylationCost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study.The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.
P2860
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@en
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@nl
type
label
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@en
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@nl
prefLabel
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@en
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@nl
P2093
P2860
P1433
P1476
The Japanese Breast Cancer Soc ...... f breast cancer, 2015 edition.
@en
P2093
Fumikata Hara
Hirofumi Mukai
Hiromitsu Akabane
Junji Tsurutani
Masato Takahashi
Rikiya Nakamura
Shigenori Nagai
Takashi Ishikawa
Tomohiko Aihara
Tomomi Fujisawa
P2860
P2888
P304
P356
10.1007/S12282-016-0670-Y
P577
2016-02-24T00:00:00Z